ABBV-951

Phase 3Small molecule

AbbVie

ABBV-951 is one of 34 small molecule programs targeting Parkinson's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson's DiseaseActive, not recruiting

Parkinson's DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Parkinson's Disease

#DrugCompanyPhaseTrials

Bendopa

MMerz North America, Inc.

Approved

13 2

Dayvigo

Eisai

Approved

1 3

Ingrezza

Neurocrine Biosciences

Strattera

3 5

Hytrin

AAbbott

Phase 3

3 6

Glucophage

EMD Serono

Phase 3

2 7

Micardis

Boehringer Ingelheim

Phase 3

1 8

Ketalar

AAultman Health Foundation

Phase 2

2 9

Coreg

Akero Therapeutics

Phase 2

2 10

Uloric

Takeda

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease6 trials

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT04750226·118 enrolled

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Active, not recruiting· AbbVie logo

AbbVie·Phase 3·NCT04379050·130 enrolled

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

Completed· AbbVie logo

AbbVie·Phase 1·NCT03374917·20 enrolled

Show 3 more trials

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

Completed· AbbVie logo

AbbVie·Phase 1·NCT05094050·16 enrolled

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Completed· AbbVie logo

AbbVie·Phase 1·NCT03033498·29 enrolled

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT04380142·174 enrolled

Parkinson's Disease (PD)1 trial

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Completed· AbbVie logo

AbbVie·Phase 3·NCT03781167·244 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for ABBV-951. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-951 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-951. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

ABBV-951

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson's Disease6 trials

Parkinson's Disease (PD)1 trial

References

Drug Info

Quick Facts

Related News